Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
J.-H. Tu, D.-L. Hu, L.-L. Dai, Y. Sun, L. Fan, M. Zhang, Z.-R. Tan, Y. Chen, Z. Li & H.-H. Zhou. (2010) Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica 40:6, pages 393-399.
Read now
Read now
Nan He, Song-Lin Huang, Rong-Hua Zhu, Zhi-Rong Tan, Jie Liu, Bing Zhu & Hong-Hao Zhou. (2003) Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica 33:2, pages 211-221.
Read now
Read now
M. Sagar, R. Seensalu, G. Tybring, M.-L. Dahl, L. Bertilsson. (1998) CYP2C19 Genotype and Phenotype Determined with Omeprazole in Patients with Acid-Related Disorders with and without Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 33:10, pages 1034-1038.
Read now
Read now
Articles from other publishers (76)
Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi & Jasper Dingemanse. (2023)
Effect of nivasorexant (
ACT
‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome
P450
probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
. Pharmacology Research & Perspectives 11:5.
Crossref
Crossref
Marion Anliker‐Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van den Anker, Benjamin Berger & Priska Kaufmann. (2023)
Evaluation of the cytochrome
P450 2C19
and
3A4
inhibition potential of the complement factor 5a receptor 1 antagonist
ACT
‐1014‐6470 in vitro and in vivo
. Clinical and Translational Science 16:7, pages 1220-1231.
Crossref
Crossref
Uchu Meade, Nadia Gabriel, Roshni Patel, Maryam Clark, Pritha Singh, Jeremy M. D. Nightingale & Richard Ng Kwet Shing. 2023. Intestinal Failure. Intestinal Failure
699
716
.
Joo Young Na, Inseung Jeon, Jangsoo Yoon, Yewon Choi, Seo Hyun Yoon, Kyung‐Sang Yu & Jae‐Yong Chung. (2021) Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects. Clinical Pharmacology in Drug Development 10:12, pages 1469-1477.
Crossref
Crossref
Jessica C. Wise, Kristopher J. Hughes, Scott Edwards, Glenn A. Jacobson, Christian K. Narkowicz & Sharanne L. Raidal. (2020) Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. Journal of Veterinary Internal Medicine 35:1, pages 620-631.
Crossref
Crossref
Alicia Regueiro-Ren. 2021. Applications of Heterocycles in the Design of Drugs and Agricultural Products. Applications of Heterocycles in the Design of Drugs and Agricultural Products
1
30
.
Rajnish Kumar, Amit Kumar, Agneta Nordberg, Bengt Långström & Taher Darreh‐Shori. (2020) Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia. Alzheimer's & Dementia 16:7, pages 1031-1042.
Crossref
Crossref
Won Kyung Kim, Hun Hwi Cho, Gi Won Lee, Yong Woon Jeong, Jin Su Kim, Alessio Bucciarelli, Jeong Eun Song & Gilson Khang. (2019) Alleviated Side Effects and Improved Efficiency of Omeprazole Using Oral Thin Film: In Vitro Evaluation. Macromolecular Research 28:5, pages 417-424.
Crossref
Crossref
E. Gordon DePuey. (2018) Gastric wall uptake of Tc-99m sestamibi: Techniques to decrease uptake and minimize its consequences in myocardial perfusion SPECT. Journal of Nuclear Cardiology 27:2, pages 674-681.
Crossref
Crossref
Jan de Jong, Nahor Haddish-Berhane, Peter Hellemans, James Jiao, Juthamas Sukbuntherng & Daniele Ouellet. (2018) The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemotherapy and Pharmacology 82:2, pages 299-308.
Crossref
Crossref
Rohit Singh, Vikas Kumar, Sonali S. Bharate & Ram A. Vishwakarma. (2017) Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis. Bioorganic & Medicinal Chemistry 25:20, pages 5513-5521.
Crossref
Crossref
Hien Van Nguyen, Namhyun Baek & Beom-Jin Lee. (2017) Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. International Journal of Pharmaceutics 523:1, pages 189-202.
Crossref
Crossref
Jin-Liang Zhang, Min Liu, Qing Yang, Shi-Yong Lin, Hong-Bo Shan, Hui-Yun Wang & Guo-Liang Xu. (2017) Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World Journal of Gastroenterology 23:14, pages 2575.
Crossref
Crossref
Ahmed Al Subaie, Elham Emami, Iskandar Tamimi, Marco Laurenti, Hazem Eimar, Mohamed-Nur Abdallah & Faleh Tamimi. (2016) Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae. Journal of Clinical Periodontology 43:2, pages 193-203.
Crossref
Crossref
Stephânia Katurchi Mendes Mélo, Tito Alves Santiago, Thaisa de Lima Duarte, José Mário Girão Abreu & Hélio Cordeiro Manso Filho. (2014) A Proton-Pump Inhibitor Modifies the Concentration of Digestion Biomarkers in Healthy Horses. Journal of Equine Veterinary Science 34:11-12, pages 1318-1323.
Crossref
Crossref
Ehab R. Bendas & Aly A. Abdelbary. (2014) Instantaneous enteric nano-encapsulation of omeprazole: Pharmaceutical and pharmacological evaluation. International Journal of Pharmaceutics 468:1-2, pages 97-104.
Crossref
Crossref
J E Sager, J D Lutz, R S Foti, C Davis, K L Kunze & N Isoherranen. (2014) Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4. Clinical Pharmacology & Therapeutics 95:6, pages 653-662.
Crossref
Crossref
R Leong, M L T Vieira, P Zhao, Y Mulugeta, C S Lee, S-M Huang & G J Burckart. (2012) Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials. Clinical Pharmacology & Therapeutics 91:5, pages 926-931.
Crossref
Crossref
Eileen B. Lawson, Jerry C. Wu, R. Michael Baldwin, Magnus Ingelman-Sundberg, Staffan Rosenborg, Dong-Seok Yim, Ophelia Q. P. Yin, Edmund V. Capparelli & Joseph D. Ma. (2011) Omeprazole limited sampling strategies to predict area under the concentration–time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. European Journal of Clinical Pharmacology 68:4, pages 407-413.
Crossref
Crossref
Sadayuki Hashioka, Andis Klegeris & Patrick L. Mcgeer. (2011) Proton pump inhibitors reduce interferon‐γ‐induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia 59:5, pages 833-840.
Crossref
Crossref
Laurian Vlase, Maria Neag, Adina Popa, Dana Muntean & Sorin E. Leucuta. (2010) Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Current Therapeutic Research 71:6, pages 360-368.
Crossref
Crossref
M. Gabello, M. C. Valenzano, M. Barr, P. Zurbach & J. M. Mullin. (2009) Omeprazole Induces Gastric Permeability to Digoxin. Digestive Diseases and Sciences 55:5, pages 1255-1263.
Crossref
Crossref
Abdullah A. Al-Badr. 2010.
151
262
.
B. L. Chen, Y. Chen, J. H. Tu, Y. L. Li, W. Zhang, Q. Li, L. Fan, Z. R. Tan, D. L. Hu, D. Wang, L. S. Wang, D. S. OuYang & H. H. Zhou. (2009) Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms. The Journal of Clinical Pharmacology 49:5, pages 574-581.
Crossref
Crossref
Sadayuki Hashioka, Andis Klegeris & Patrick L. McGeer. (2009) Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Experimental Neurology 217:1, pages 177-183.
Crossref
Crossref
Jeffrey N. Hemenway. 2007. Prodrugs. Prodrugs
1313
1321
.
Dae Y. Lee, Hyun S. Shin, Soo K. Bae & Myung G. Lee. (2006) Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. Biopharmaceutics & Drug Disposition 27:5, pages 209-218.
Crossref
Crossref
Hideki WATANABE, Yoshiaki TAKEUCHI & Michio IMAWARI. (2006) Mosapride Citrate Beneficially Affects Pharmacokinetic Parameters of Omeprazole. The Showa University Journal of Medical Sciences 18:1, pages 43-49.
Crossref
Crossref
Ernst Eypasch, Edmund A.M. Neugebauer, F. Fischer, Hans Troidl, A.L. Blum, D. Collet, A. Cuschieri, B. Dallemagne, H. Feussner, K.-H. Fuchs, H. Glise, C.K. Kum, T. Lerut, L. Lundell, H.E. Myrvold, A. Peracchia, H. Petersen & J.J.B. van Lanschot. 2006. EAES Guidelines for Endoscopic Surgery. EAES Guidelines for Endoscopic Surgery
97
124
.
A. Leucuta, L. Vlase, D. Farcau & M. Nanulescu. (2004) A PHARMACOKINETIC INTERACTION STUDY BETWEEN OMEPRAZOLE AND THE H2-RECEPTOR ANTAGONIST RANITIDINE. Drug Metabolism and Drug Interactions 20:4.
Crossref
Crossref
Héctor M. Gonzalez, Elba M.T. Romero, A.L. Aaron Peregrina, Teresa de J.C. Chávez, Estanislao Escobar‐Islas, Lozano K. Felipe & Carlos Hoyo‐Vadillo. (2013) CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans. The Journal of Clinical Pharmacology 43:11, pages 1211-1215.
Crossref
Crossref
Ricardo Mathias Orlando & Pierina Sueli Bonato. (2003) Simple and efficient method for enantioselective determination of omeprazole in human plasma. Journal of Chromatography B 795:2, pages 227-235.
Crossref
Crossref
J. P. Gisbert, L. González, X. Calvet, M. Roqué, R. Gabriel & J. M. Pajares. (2002)
Proton pump inhibitors versus H
2
‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer
. Alimentary Pharmacology & Therapeutics 15:7, pages 917-926.
Crossref
Crossref
M. Sagar, L. Bertilsson, M. Stridsberg, A. Kjellin, S. Mårdh & R. Seensalu. (2001) Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Alimentary Pharmacology & Therapeutics 14:11, pages 1495-1502.
Crossref
Crossref
Dennis L. Avner. (2000) Clinical experience with pantoprazole in gastroesophageal reflux disease. Clinical Therapeutics 22:10, pages 1169-1185.
Crossref
Crossref
Mohamed Sagar, Gunnel Tybring, Marja–Liisa Dahl, Leif Bertilsson & Rein Seensalu. (2000) Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119:3, pages 670-676.
Crossref
Crossref
Daniel S. Streetman, Joseph S. BertinoJrJr & Anne N. Nafziger. (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:3, pages 187-216.
Crossref
Crossref
Yuyuan Li, Weihong Sha, Yuqiang Nie, Huisheng Wu, Qingzhu She, Shoujun Dai, Lin Jia & Weixiong Yu. (2001) Effect of intragastric pH on control of peptic ulcer bleeding. Journal of Gastroenterology and Hepatology 15:2, pages 148-154.
Crossref
Crossref
N. Yoshida, T. Yoshikawa, Y. Tanaka, N. Fujita, K. Kassai, Y. Naito & M. Kondo. (2000) A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Alimentary Pharmacology & Therapeutics 14, pages 74-81.
Crossref
Crossref
Barkun, Cockeram, Plourde & Fedorak. (2001) Review article: acid suppression in non‐variceal acute upper gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 13:12, pages 1565-1584.
Crossref
Crossref
G. Garcı́a-Encina, R. Farrán, S. Puig & L. Martı́nez. (1999) Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis 21:2, pages 371-382.
Crossref
Crossref
Connor, Seow, Ngu & Katelaris. (2001)
The effect of dosing with omeprazole on the accuracy of the
13
C‐urea breath test in
Helicobacter pylori
‐infected subjects
. Alimentary Pharmacology & Therapeutics 13:10, pages 1287-1293.
Crossref
Crossref
Lew. (1999) Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Alimentary Pharmacology & Therapeutics 13, pages 11-16.
Crossref
Crossref
SAGAR, JANCZEWSKA, LJUNGDAHL, BERTILSSON & SEENSALU. (1999)
Effect of CYP2C19 polymorphism on serum levels of vitamin B
12
in patients on long-term omeprazole treatment
. Alimentary Pharmacology & Therapeutics 13:4, pages 453-458.
Crossref
Crossref
Tetsuya SEKI, Nobuyuki OHBA, Hitoshi FUNATOMI, Kazuya UTAHASHI, Keiichiro YONEYAMA & Keiji MITAMURA. (1999) A Case of Omerpazole-induced Gynecomastia Not Ascribed to Hormonal Abnormalities. The Showa University Journal of Medical Sciences 11:1, pages 45-52.
Crossref
Crossref
Jia-Qing Huang & Richard H. Hunt. 1999. Proton Pump Inhibitors. Proton Pump Inhibitors
63
78
.
Paolo L. Peghini, Philip O. Katz & Donald O. Castell. (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 115:6, pages 1335-1339.
Crossref
Crossref
Lew, Barbuti, Kovacs, Sytnic, Humphries & Walsh. (1998) An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Alimentary Pharmacology & Therapeutics 12:7, pages 667-672.
Crossref
Crossref
Paolo L Peghini, Philip O Katz, Nicole A Bracy & Donald O Castell. (1998) Nocturnal Recovery of Gastric Acid Secretion With Twice-Daily Dosing of Proton Pump Inhibitors. American Journal of Gastroenterology 93:5, pages 763-767.
Crossref
Crossref
K. Ito, T. Iwatsubo, S. Kanamitsu, Y. Nakajima & Y. Sugiyama. (1998) QUANTITATIVE PREDICTION OF IN VIVO DRUG CLEARANCE AND DRUG INTERACTIONS FROM IN VITRO DATA ON METABOLISM, TOGETHER WITH BINDING AND TRANSPORT. Annual Review of Pharmacology and Toxicology 38:1, pages 461-499.
Crossref
Crossref
M SörbergH HanbergerM NilssonL E Nilsson. (1997) Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrobial Agents and Chemotherapy 41:10, pages 2218-2223.
Crossref
Crossref
Gunnel Tybring, Ylva Böttiger, Jolanta Widén & Leif Bertilsson. (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects*. Clinical Pharmacology & Therapeutics 62:2, pages 129-137.
Crossref
Crossref
Yoseph Caraco, Per-Olaf Lagerstrom & Alastair J.J. Wood. (1996) Ethnic and genetic determinants of omeprazole disposition and effect*. Clinical Pharmacology & Therapeutics 60:2, pages 157-167.
Crossref
Crossref
Luigi Benini, Greta Castellani, Enrico Bardelli, Carlo Sembenini, Maria Teresa Brentegani, Silvio Caliari & Italo Vantini. (1996) Omeprazole causes delay in gastric emptying of digestible meals. Digestive Diseases and Sciences 41:3, pages 469-474.
Crossref
Crossref
Masayuki Suzuki, Mikiji Mori, Soichiro Miura, Makoto Suematsu, Dai Fukumura, Hiroyuki Kimura & Hiromasa Ishii. (1996) Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radical Biology and Medicine 21:5, pages 727-731.
Crossref
Crossref
I. David BoughJr.Jr., Robert Thayer Sataloff, Donald O. Castell, James R. Hills, R. Matthew Gideon & Joseph R. Spiegel. (1995) Gastroesophageal reflux laryngitis resistant to omeprazole therapy. Journal of Voice 9:2, pages 205-211.
Crossref
Crossref
H StuhtH LodeP KoeppeK L RostT Schaberg. (1995) Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrobial Agents and Chemotherapy 39:5, pages 1045-1049.
Crossref
Crossref
Raymond T. Chung, David L. Jaffe & Lawrence S. Friedman. (1995) Complications of Chronic Liver Disease. Critical Care Clinics 11:2, pages 431-463.
Crossref
Crossref
S. Teyssen, S. T. Chari, J. Scheid & M. V. Singer. (1995) Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Digestive Diseases and Sciences 40:2, pages 247-255.
Crossref
Crossref
CH Wilder‐Smith, HU Bettschen & HS Merki. (2012) Individual and group dose‐responses to intravenous omeprazole in the first 24 h: pH‐feedback‐controlled and fixed‐dose infusions.. British Journal of Clinical Pharmacology 39:1, pages 15-23.
Crossref
Crossref
Kazuhide Watanabe, Katsushi Furuno, Kohei Eto, Ryozo Oishi & Yutaka Gomita. (1994) First-Pass Metabolism of Omeprazole in Rats. Journal of Pharmaceutical Sciences 83:8, pages 1131-1134.
Crossref
Crossref
J. Lance Lichtor. (1994) Pre-operative medication, fluids and chronic medication in the ambulatory setting. Current Anaesthesia & Critical Care 5:3, pages 133-141.
Crossref
Crossref
MSP Sastry, PV Diwan & DR Krishna. (2009) Comparative evaluation of ulcer prevention efficacy of orally, rectally and sublingually administered omeprazole in three acute gastric ulcer models in rats. Fundamental & Clinical Pharmacology 7:2, pages 77-80.
Crossref
Crossref
M.J. Arens & J. Dent. (1993) Acid pump blockers: what are their current therapeutic roles?. Baillière's Clinical Gastroenterology 7:1, pages 95-128.
Crossref
Crossref
Robert D. Shamburek & Mitchell L. Schubert. (1993) Pharmacology of gastric acid inhibition. Baillière's Clinical Gastroenterology 7:1, pages 23-54.
Crossref
Crossref
Firouzan Massoomi, John Savage & Christopher J. Destache. (2012) Omeprazole: A Comprehensive Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 13:1, pages 46-59.
Crossref
Crossref
Robert D. Shamburek & Mitchell L. Schubert. (1992) CONTROL OF GASTRIC ACID SECRETION. Gastroenterology Clinics of North America 21:3, pages 527-550.
Crossref
Crossref
P. Sauvet & L. Schouler. (1992) Oméprazole et fonctions hépatiques. La Revue de Médecine Interne 13:5, pages 359-363.
Crossref
Crossref
W. Scott McDougal. (1992) Metabolic Complications of Urinary Intestinal Diversion. Journal of Urology 147:5, pages 1199-1208.
Crossref
Crossref
Kent D. Katz & Daniel Hollander. (1992) Practical pharmacology and cost-effective management of peptic ulcer disease. The American Journal of Surgery 163:3, pages 349-359.
Crossref
Crossref
Thomas J. Kinahan, Antoine E. Khoury, Gordon A. McLorie & Bernard M. Churchill. (1992) Omeprazole in Post-Gastrocystoplasty Metabolic Alkalosis and Aciduria. Journal of Urology 147:2, pages 435-437.
Crossref
Crossref
Julian Katz. (1991) Acid Secretion and Suppression. Medical Clinics of North America 75:4, pages 877-887.
Crossref
Crossref
John A. Oates, Alastair J.J. Wood & Paul N. Maton. (1991) Omeprazole. New England Journal of Medicine 324:14, pages 965-975.
Crossref
Crossref
Tommy Andersson & Carl-Gunnar Regårdh. (2012) Pharmacokinetics of Omeprazole and Metabolites Following Single Intravenous and Oral Doses of 40 and 80mg. Drug Investigation 2:4, pages 255-263.
Crossref
Crossref
E. C. KLINKENBERG-KNOL & S. G. M. MEUWISSEN. (2007) Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.. Alimentary Pharmacology & Therapeutics 4:5, pages 485-495.
Crossref
Crossref
NicholasA. Wright, RobertA. Goodlad, F. Díaz De Rojas, HerbertF. Helander, Haken Larsson & Enar Carlsson. (1990) Omeprazole and genotoxicity. The Lancet 335:8694, pages 909-911.
Crossref
Crossref